Potential harms associated with 4-aminoquinoline treatment
Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Lakartidningen - 117(2020) vom: 23. Apr. |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar |
|---|
| Beteiligte Personen: |
Svensson, Markus [VerfasserIn] |
|---|
| Themen: |
4-aminoquinoline |
|---|
| Anmerkungen: |
Date Completed 07.05.2020 Date Revised 18.12.2020 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM30948782X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30948782X | ||
| 003 | DE-627 | ||
| 005 | 20231225134024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM30948782X | ||
| 035 | |a (NLM)32365215 | ||
| 035 | |a (PII)F3UD | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Svensson, Markus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential harms associated with 4-aminoquinoline treatment |
| 246 | 3 | 3 | |a Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.05.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hydroxychloroquine and chloroquine are currently being evaluated as treatment against COVID-19. These drugs are associated with some potential harms, including QTc-interval prolongation, hypoglycaemia, severe skin reactions and psychiatric effects. Use of hydroxychloroquine or chloroquine should be reserved to current indications or clinical trials, as recommended by several governmental medical products agencies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Aminoquinolines |2 NLM | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 650 | 7 | |a 4-aminoquinoline |2 NLM | |
| 650 | 7 | |a GTE5P5L97N |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 117(2020) vom: 23. Apr. |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2020 |g day:23 |g month:04 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2020 |b 23 |c 04 | ||